This document has been translated from the Japanese original for reference purposes only.
In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect or any other forms of damages arising from the translation.

November 12, 2026

To whom it may concern:

Company	D.Western Therapeutics Institute, Inc.
Representative	Yuichi Hidaka, President and CEO
	(Securities code: 4576; TSE Growth)
Contact	Sayako Matsubara, Director
TEL	052-218-8785

Announcement Regarding Application for Change of Market Segment to the Tokyo Stock Exchange Standard Market

D.Western Therapeutics Institute, Inc. (hereafter, “the Company”) hereby announces that, at a meeting of its Board of Directors held today, it resolved to apply for a change of market segment to the Tokyo Stock Exchange Standard Market, as follows.

The Company’s vision is “Innovative New Drugs to the World from Japan,” and it is promoting the research and development of new drugs, primarily in the ophthalmology field, by leveraging its proprietary core drug discovery technology. The Company’s first product was launched in 2014, and since then, a total of four products have been launched. In addition, the Company currently has four late-stage pipeline assets at Phase III or beyond and is advancing their development with the aim of delivering them to patients as early as possible. In particular, the glaucoma treatment “H-1337” and the regenerative medical product “DWR-2206” are positioned as key development products that will drive the Company’s next stage of growth.

The Company believes that, in order to enhance corporate value over the medium to long term, it is important to steadily make R&D investments toward building its future revenue base while continuing efforts to maximize the value of each development pipeline.

As a result of comprehensively considering the characteristics of the Company’s business, the business environment, and other factors, the Company determined that conducting business operations in a market environment better suited to its current business stage and future growth strategy is important for steadily advancing its medium- to long-term growth strategy and pursuing sustainable enhancement of corporate value. Accordingly, the Company decided to apply for a change of market segment to the Standard Market.

There will be no change in the direction of growth pursued by the Company following the change of market segment. The Company will continue to work to maximize the value of its development pipeline, including “H-1337” and “DWR-2206,” and expand its lineup of marketed products, while enhancing constructive dialogue and information dissemination with shareholders and investors, thereby striving to enhance corporate value over the medium to long term.

At present, whether and when the Tokyo Stock Exchange will approve the application is uncertain, and the application for a change of market segment does not guarantee listing on the Standard Market.

If any matters requiring disclosure arise in connection with this matter, the Company will promptly make an announcement.

End